𩺠å
§ç§å°ç§èåç
1ïžâ£ Hib Vaccine Schedule (Taiwan)
- 2/4/6 mo + booster 18 mo
- å
¬è²» (NIP)
- ç¡èŸ, immunocompromise â booster åŸå¹Žéœ¡ if not previously vaccinated
- Catch-up to 5 yr if unvaccinated
2ïžâ£ Post-Vaccine Era Epiglottitis
- Adult > child now (incidence shifted)
- æ¶µè broader pathogens: GAS, S. aureus, S. pneumo, NTHi
- Empirical: ceftriaxone + vanco (community), broaden if hospital risk
- å³äœ¿ vaccinate åŸ NTHi å¯èœ
3ïžâ£ COPD Exacerbation Microbiology
- ~ 50% bacterial cause; remaining viral / non-infectious
- NTHi most common (~ 30%), M. catarrhalis (~ 15%), S. pneumoniae (~ 15%)
- Pseudomonas in severe COPD with FEV1 < 50%, frequent abx, hospitalize
- Treatment: amox-clav, FQ, macrolide (Anthonisen criteria)
4ïžâ£ HACEK IE Update
- Gone from âculture-negativeâ to identifiable
- 5-7 day automated systems detect most
- ESC 2023 / AHA 2024: ceftriaxone 2 g q24h à 4 wk (native) â once-daily, often OPAT
- æ¿ä»£: amp-sulbactam, FQ
- Endocarditis general workup: TEE, surgical consult if vegetation > 10 mm, abscess, HF
5ïžâ£ Chancroid + HIV
- Genital ulcers (chancroid, HSV, syphilis) â HIV transmission risk â
- HIV â chancroid prevalence + slower healing
- å€ ulcer / atypical â think HIV co-infection
- Always test HIV + syphilis + HSV + Chlamydia/LGV
6ïžâ£ Moraxella catarrhalis éå¥ Neisseria
| Sugar fermentation |
None |
Glucose ± maltose |
| DNase |
+ |
- |
| Growth 22°C |
+ |
- |
| Tributyrin hydrolysis |
+ |
- |